Fate Therapeutics (FATE) Change in Accured Expenses (2012 - 2026)

Fate Therapeutics has reported Change in Accured Expenses for 15 years, with the latest figure at -$5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 41.24% year-over-year to -$5.8 million; the trailing twelve-month figure through Mar 2026 stood at -$5.0 million (up 28.72% YoY), and the FY2025 full-year result was -$9.0 million, down 443.47% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.8 million, down from $865000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $10.3 million in Q3 2022, with the low at -$20.4 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$1.8 million across 5 years, with a median of -$550000.0 in 2025.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 483.82% — and 2024, when it soared 182.03%.
• Fate Therapeutics' Change in Accured Expenses stood at $3.4 million in 2022, then sank by 155.89% to -$1.9 million in 2023, then surged by 134.6% to $655000.0 in 2024, then jumped by 32.06% to $865000.0 in 2025, then tumbled by 767.51% to -$5.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.8 million (Q1 2026), $865000.0 (Q4 2025), and -$550000.0 (Q3 2025), per Business Quant data.